Samsung Biologics FY 2025 Annual Report
Beta

Filed: March 12, 2026· period ending December 31, 2025DART

Samsung Biologics annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 12, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Samsung Biologics FY 2025 Annual Report Analysis

Business Overview

• Pure-play CDMO focus achieved via Nov 2025 spin-off of Samsung Epis Holdings (삼성에피스홀딩스), separating biosimilar business to eliminate conflict-of-interest concerns
• FY2025 consolidated revenue KRW 4.557T (+30% YoY), operating profit KRW 2.069T (+57% YoY); total production capacity 785,000L across 5 plants in Songdo

Management Discussion & Analysis

• Samsung Biologics FY2025 revenue KRW 4,557B, up 30.31% YoY; operating profit KRW 2,069B, up 56.60% YoY; net income KRW 1,784B, up 64.71% YoY
• Growth driven by Plants 1–3 full utilization, Plant 4 ramp-up, and favorable FX impact on CDMO revenue

Risk Factors

• FX risk primary exposure: sales, purchases, and borrowings denominated in USD (functional currency KRW); forward contracts available as hedge tool but not currently in use
• Credit risk maximum exposure equals carrying value of financial assets; client creditworthiness assessed via financial statements and pipeline development stage

Samsung Biologics FY 2025 Key Financial Metrics
DART

Total Assets

KRW 11.06T

▼ -36.2% YoY

Operating Cash Flow

KRW 2.25T

▲ +35.5% YoY

CapEx

KRW 1.39T

▲ +6.8% YoY

Source: KIFRS consolidated financial data from Samsung Biologics annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding